Patents by Inventor Tomas Fex
Tomas Fex has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348444Abstract: There is provided novel pharmaceutical compounds of formula I (I) wherein R1, R2, R3, R4, R5, n and Z are as defined herein are as defined herein, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.Type: ApplicationFiled: September 1, 2021Publication date: November 2, 2023Inventors: Tomas Fex, Bengt Ohlsson
-
Publication number: 20230114153Abstract: There is provided herein a compound of formula (I), wherein R1, R2, R3, R4, R5 and Z are as defined herein, for use in the treatment of a disease or condition in which activation of AT2 receptors is desired or required but in which inhibition of CYPs is not desired. Such compounds are particularly useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.Type: ApplicationFiled: March 18, 2021Publication date: April 13, 2023Applicant: Vicore Pharma ABInventors: Tomas Fex, Bengt Ohlsson, Johan Raud
-
Publication number: 20220388994Abstract: There is provided herein a compound of formula I, wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.Type: ApplicationFiled: September 18, 2020Publication date: December 8, 2022Inventors: Tomas Fex, Bengt Ohlsson
-
Publication number: 20180338964Abstract: Described are a group of isoxazol-3(2H)-one analogues and their use in topical formulations for the treatment and prophylaxis of dermatological disorders.Type: ApplicationFiled: August 2, 2018Publication date: November 29, 2018Applicant: Emeriti Pharma ABInventors: Tomas Fex, Nils David Gustafsson
-
Publication number: 20170360766Abstract: Described are a group of isoxazol-3(2H)-one analogues and their use in topical formulations for the treatment and prophylaxis of dermatological disorders.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Applicant: Emeriti Pharma ABInventors: Tomas Fex, Nils David Gustafsson
-
Patent number: 8415378Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprisType: GrantFiled: April 6, 2010Date of Patent: April 9, 2013Assignee: AstraZeneca ABInventors: Jonas Boström, Leifeng Cheng, Tomas Fex, Michael Karle, Daniel Pettersen, Peter Schell
-
Publication number: 20100261755Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprisingType: ApplicationFiled: April 6, 2010Publication date: October 14, 2010Applicant: AstraZeneca ABInventors: Jonas BOSTRÖM, Leifeng Cheng, Tomas Fex, Michael Karle, Daniel Pettersen, Peter Schell
-
Publication number: 20080293587Abstract: The present invention relates to a method of screening a biological target for transient weak interactions between the target and a library of ligands. The method includes the provision of a composition comprising a biological target and the provision of a plurality of stationary phases from such a composition. A plurality of ligand compositions is transported to the stationary phases to establish contacts between the ligands and the biological targets. Zonal retardation information are collected for each ligand, downstream of the stationary phases in order to select ligands with dissociation constants (Kd) in the range of 0.01 to 10 mM, exhibiting weak affinity to the target.Type: ApplicationFiled: October 25, 2006Publication date: November 27, 2008Inventors: Sten Ohlson, Siamak Shoravi, Tomas Fex, Roland Isaksson
-
Patent number: 6642249Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined.Type: GrantFiled: June 26, 2002Date of Patent: November 4, 2003Assignee: Active Biotech ABInventors: Per Axel Björk, Tomas Fex, Lars Olof Göran Pettersson, Pous Sørensen, Dorthe Da Graça Thrige
-
Patent number: 6605616Abstract: The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R′ is methyl, methoxy, fluoro, chloro, bromo, azido, trifluorometlhyl, or OCHxFy, wherein x=0−2, y=1−3 with the. proviso that x+y=3; R″ is hydrogen, fluoro or chloro; with the proviso that R″ is fluoro or chloro only when R′ is fluoro or chloro; R4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R5 is dimethylamino or nitro; R6 is hydrogen; and when R′ is azido R5 is also ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCHxFy, wherein x=0−2, y=1−3 with the proviso that x+y=3, or R5 and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier.Type: GrantFiled: July 21, 2000Date of Patent: August 12, 2003Assignee: Active Biotech ABInventors: Anders Björk, Stig Jönsson, Tomas Fex, Gunnar Hedlund
-
Patent number: 6593343Abstract: Compounds of formula (I) and tautomers thereof are effective for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation.Type: GrantFiled: April 25, 2002Date of Patent: July 15, 2003Assignee: Active Biotech ABInventors: Anders Björk, Stig Jönsson, Tomas Fex, Gunnar Hedlund
-
Publication number: 20030022913Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.Type: ApplicationFiled: June 26, 2002Publication date: January 30, 2003Inventors: Per Axel Bjork, Tomas Fex, Lars Olof Goran Pettersson, Poul Sorensen, Dorthe Da Graca Thrige
-
Publication number: 20020173520Abstract: The invention is related to compounds of general formula (I) 1Type: ApplicationFiled: April 25, 2002Publication date: November 21, 2002Applicant: Active Biotech ABInventors: Anders Bjork, Stig Jonsson, Tomas Fex, Gunnar Hedlund
-
Publication number: 20020173519Abstract: Compounds of formula (I) 1Type: ApplicationFiled: April 25, 2002Publication date: November 21, 2002Applicant: Active Biotech ABInventors: Anders Bjork, Stig Jonsson, Tomas Fex, Gunnar Hedlund
-
Patent number: 6423220Abstract: A chromatographic column for simultaneous purification of several compounds in a sample by dry column chromatography comprised by a plastic tube and containing a sorbent is described, wherein there is an empty volume on top of the sorbent large enough to hold the amount of developing solvent needed to develop the column, wherein the plastic material is transparent or semitransparent to UV and visible light and can be cut with a sharp object, and wherein the sorbent particle size is <40&mgr; and contains a fluorescent material.Type: GrantFiled: November 13, 2000Date of Patent: July 23, 2002Assignee: Trikonex ABInventor: Tomas Fex
-
Patent number: 6133285Abstract: The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCH.sub.x F.sub.y, whereinx=0-2, y=1-3 with the proviso that x+y=3, R" is hydrogen, fluoro or chloro; with the proviso that R" is fluoro or chloro only when R' is fluoro or chloro; R.sub.4 is hydrogen or pharmaceutically acceptable inorganic or organic cations;R.sub.5 is ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCH.sub.x F.sub.y, or OCH.sub.2 CH.sub.x F.sub.y wherein x=0-2, y=1-3 with the proviso that x+y=3;R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 taken together are methylenedioxy; and any tautomer thereof.The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier.Type: GrantFiled: July 14, 1999Date of Patent: October 17, 2000Assignee: Active Biotech ABInventors: Anders Bjork, Stig Jonsson, Tomas Fex, Gunnar Hedlund
-
Patent number: 6121287Abstract: The invention is related to compounds of general formula (I) ##STR1## wherein R is Me, Et, n-Pr, iso-Pr, n-Bu, iso-Bu, sec.-Bu or allyl; R' is hydrogen, Me, MeO, fluoro, chloro, brorno, CF.sub.3, or OCH.sub.x F.sub.y ; R" is hydrogen or fluoro, with the proviso that R" is fluoro when R' is fluoro; and further when R' and R" are both hydrogen, R is not Me; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from MeS, EtS, n-PrS, iso-PrS, MeSO, EtSO, MeSO.sub.2 and EtSO.sub.2 ; wherein x=0-2, y=1-3 with the proviso that x+y=3; and Me is methyl, Et is ethyl, Pr is propsy and Bu is butyl; and any tautomer, optical isomer and racemate thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier.Type: GrantFiled: July 14, 1999Date of Patent: September 19, 2000Assignee: Active Biotech ABInventors: Anders Bjork, Stig Jonsson, Tomas Fex, Gunnar Hedlund
-
Patent number: 6077851Abstract: The invention relates to compounds of general formula (I) ##STR1## wherein R is selected from ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; R.sub.4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R.sub.5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, CF.sub.3, and OCH.sub.x F.sub.y ; wherein x=0-2, y=1-3 with the proviso that x+y=3; R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 taken together are methylenedioxy; and any tautomer hereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering a compound having the formula (I) to said mammal.Type: GrantFiled: April 22, 1999Date of Patent: June 20, 2000Assignee: Active Biotech ABInventors: Anders Bjork, Stig Jonsson, Tomas Fex, Gunnar Hedlund
-
Patent number: 5734071Abstract: A process for separating lipophilic compounds from other lipophilic compounds and a kit therefore are described, said process comprises the steps of:a) providing a mixture of the lipophilic compounds;b) providing urea dissolved in an inert solvent or solvent mixture in which said lipophilic compounds are at most only slightly soluble;c) contacting the mixture of lipophilic compounds with the urea, whereby said urea complex forming lipophilic compounds form complexes with the urea,d) separating the whole mixture into a two-phase mixture with lipophilic compounds forming a first phase and the solvent or solvent mixture forming a second phase, where the complexes formed are present as solids in the second phase, and the lipophilic compounds, which have not been complexed with urea, are present in the first phase,e) separating, and optionally purifying, the first phase from the second phase;f) heating the second phase to break the complexes and release the lipophilic compounds, thereby forming a two-phase mixtureType: GrantFiled: April 16, 1996Date of Patent: March 31, 1998Assignee: Trikonex ABInventors: Tomas Fex, Gunnar Olsson
-
Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation
Patent number: 4937245Abstract: A compound having the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein all the symbols are defined in the specification; having valuable pharmaceutical properties, useful for the treatment of mental disorders, such as psychoses, depression and anxiety.Type: GrantFiled: November 30, 1988Date of Patent: June 26, 1990Inventors: Tomas Fex, Knut G. Olsson, Aina L. Abramo, Erik G. Christensson, Torbjorn E. Lundstedt